Home›Trial›NCT06989437
🔬NCT06989437Phase 2Phase 3RECRUITING

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study Summary

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

Conditions
CachexiaMetastatic Pancreatic Ductal Adenocarcinoma
Interventions / Drugs
ponsegromabplacebo
View on ClinicalTrials.gov ↗
Sponsor
PFE
Pfizer Inc
Diversified Pharma
F34/100
Study Details
Enrollment982 participants
Primary Completion—
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.190800+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.